GAITHERSBURG, Md., Dec. 12, 2018 /PRNewswire/ -- The Global
Health Innovative Technology (GHIT) Fund has awarded VLP
Therapeutics a $3.9 million grant to
further develop a novel tetravalent dengue virus-like particle
vaccine.
"The GHIT Fund's commitment is an important step for the further
validation of our virus-like particle vaccine technology. We are
grateful to the GHIT Fund for its continued support of this
important vaccine. Their past support years enabled us to show
proof of concept for our novel dengue VLP vaccine in critical
animal studies, and the new grant will enable further development
and manufacturing of this novel Dengue vaccine candidate," says Dr Wataru
Akahata, CEO of VLP Therapeutics.
VLP Therapeutics has developed a novel dengue VLP vaccine using
its proprietary technology. VLP Therapeutics' previously funded
GHIT project demonstrated the dengue VLP vaccine's efficacy and
safety in preclinical studies including non-human primates. The
current project is focused on producing this VLP vaccine to conduct
clinical trials. VLP Therapeutics is partnering with The Japan
National Institute of Infectious Disease, Nagasaki University, Latham Biopharm Group and
the Johns Hopkins University Bloomberg
School of Public Health.
Contact:
Jacob Licht,
Chief Operating Officer
240-421-9755
jlicht@vlptherapeutics.com
VLP Therapeutics
VLP Therapeutics was established in
2013 with a mission to create next-generation virus-like particles
to transform traditional vaccine therapies. VLP Therapeutics
modifies viruses to create novel cancer and infectious disease
vaccine candidates, and the Company's virus-like particle vaccines
have proven to be highly immunogenic in multiple animal models. VLP
Therapeutics anticipates initiating a human trial of its Malaria
vaccine in early 2019.
Global Health Innovative Technology (GHIT)
The GHIT
Fund aims to facilitate global R&D partnerships for the
discovery and development of new healthcare technologies for the
developing world. The GHIT Fund invests in global R&D
partnerships through a grant-making mechanism, thereby facilitating
international partnerships that bring Japanese innovation,
investment, and leadership to the global fight against infectious
diseases and poverty in the developing world. The GHIT Fund
partners include representatives from the Japanese Government, the
pharmaceutical industry, the Bill & Melinda Gates Foundation,
and the Wellcome Trust.
About Dengue
Dengue is a mosquito-borne viral disease
that is one of the most serious public health problems worldwide.
It is estimated that more than half of the world population is at
risk of a dengue infection.
View original
content:http://www.prnewswire.com/news-releases/vlp-therapeutics-awarded-3-9-million-grant-by-global-health-innovative-technology-fund-for-further-development-of-dengue-vaccine-300764472.html
SOURCE VLP Therapeutics, LLC